
|Articles|August 15, 2004
Olopatadine 0.2% provides extended efficacy during peak pollen periods
Fort Lauderdale, FL-A new formulation of an anti-allergy medication, olopatadine HCl ophthalmic solution 0.2% (Patanol II, Alcon Laboratories), provides two important advantages. It allows once-daily dosing, which increases patient compliance, and maintains the level of effectiveness of the original formulation, olopatadine 0.1%, during peak pollen seasons for an extended period up to 24 hours, according to Jack Greiner, DO, PhD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Beyond the surface: Tackling complex dry eye cases
2
SpyGlass Pharma releases positive data from 2 trials of Bimatoprost Drug Pad-IOL System
3
Redefining glaucoma care: Where innovation meets clinical insight
4
Seborrheic dermatitis linked to multiple epithelial barrier diseases
5


















































.png)


